Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.
Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.
复制标题
根据结直肠癌 (CRC) 位置对 EGFR 通路进行分子分析：对单个机构的 1,001 名患者进行分析。
DOI：
10.1200/jco.2014.32.15_suppl.3597
复制
发表时间：
2014
影响因子：
45.3
通讯作者：
N. Mizunuma
中科院分区：
文献类型：
--
作者：
E. Shinozaki;Y. Miki;M. Ueno;M. Igarashi;M. Suenaga;K. Chin;M. Ozaka;M. Ogura;Toshiharu Yamaguchi;N. Mizunuma
3597 背景：在 NCIC CTG CO.17 试验的亚分析中，结肠癌的位置（右侧与左侧）被报告为西妥昔单抗获益的预测因子。另一方面，回顾性分析已确定 KRAS（包括密码子 61、密码子 146、BRAF、NRAS 或 PIK3CA 突变）作为抗 EGFR 治疗的潜在阴性预测因素。该分析旨在根据大型队列中 CRC 的位置揭示 EGFR 通路中这些突变的发生率。方法：本研究对2012年1月至2013年10月连续收治的1001例CRC患者进行分析。使用 Luminex Assay（MABGEN 和 GENOSEARCH Mu-PACK，MBL）对档案样本进行 EGFR 通路的多重基因分型，用于 KRAS（包括密码子 61 和 146、BRAF、NRAS 和 PIK3CA）。我们检查了突变谱、临床数据和 CRC 位置之间的相关性。通过卡方检验进行统计分析。结果：突变的发生率； KRAS 密码子 12 和 13、密码子 61 和 146、BRAF、NRAS...
3597 Background: Location of colon cancer (right-sided versus left-sided) was reported as a predictor of benefit from cetuximab in the subanalysis of NCIC CTG CO.17 trial. On the other hand, retrospective analyses have identified KRAS including codon61, codon146, BRAF, NRAS, or PIK3CA mutations as potentially negative predictive factors for anti EGFR treatments. This analysis aimed to reveal the prevalence of these mutations in the EGFR pathway according to location of CRC in a large cohort. Methods: Consecutive patients of 1,001 CRC from January 2012 to October 2013 were analyzed in this study. Multiplex genotyping of EGFR pathway was performed on archival samples using Luminex Assay (MABGEN and GENOSEARCH Mu-PACK, MBL) for KRAS including codons 61 and 146, BRAF, NRAS, and PIK3CA. We examined the correlation among mutation profile, clinical data and location of CRC. Statistical analysis was conducted by chi-square test. Results: The incidence of mutations; KRAS codon12 and 13, codon61 and 146, BRAF, NRAS...